We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
- Recent ZBH Stock Price: $139.62
- Yearly Gain for ZBH stock: 19.49%
- Market Cap for ZBH stock: $29.16B
- P/E Ratio for ZBH stock: 66.786
Will ZBH's stock price go up? Is there an accurate ZBH stock forecast available?
TipRanks.com reports that Zimmer Biomet Holdings currently has 16 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $142.27. The target pricing ranges from a high ZBH forecast of $160.00 down to a low forecast of $112.00. Zimmer Biomet Holdings (ZBH)’s last closing stock price was $139.62 which would put the average price target at 7.20% upside.
In addition, TradingView issued a Buy rating for ZBH stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ZBH stock.
Other analysts covering ZBH include:
- Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 160 on 22 hours ago
- Kyle Rose of Canaccord Genuity issued a Hold rating with the price target of $ 150 on 22 hours ago
- Cecilia Furlong of Morgan Stanley issued a Hold rating with the price target of $ 150 on 22 hours ago
- Travis Steed of Bank of America Securities issued a Hold rating with the price target of $ 160 on 22 hours ago
If you are wondering if ZBH is a good stock to buy, here are 3rd party ratings for ZBH stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 42% (106 out of 250)
What is the sentiment on the street regarding Zimmer Biomet Holdings? (Current ratings compiled by TipRanks.com)
- News Sentiment for ZBH stock: Very Bullish
- Blogger Consensus for ZBH stock: Bullish
- Media Buzz for ZBH stock: Very High
- Insider Signal for ZBH stock: ―
- Investor Sentiment for ZBH stock: Very Negative
- Hedge Fund signal for ZBH stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ZBH stock including scouring the social networks like ZBH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ZBH stock chart >>
Summary: Hologic Inc. develops, manufactures, and supplies diagnostics, medical imaging systems and surgical products which cater to the healthcare needs of women. Hologic operates through the following four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.
- Recent HOLX Stock Price: $84.09
- Yearly Gain for HOLX stock: 19.88%
- Market Cap for HOLX stock: $21.62B
- P/E Ratio for HOLX stock: 29.279
Will HOLX's stock price go up? Is there an accurate HOLX stock forecast available?
TipRanks.com reports that Hologic currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $92.50. The target pricing ranges from a high HOLX forecast of $105.00 down to a low forecast of $85.00. Hologic (HOLX)’s last closing stock price was $84.09 which would put the average price target at 10.00% upside.
In addition, TradingView issued a Neutral rating for HOLX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on HOLX stock.
Other analysts covering HOLX include:
- Anthony Petrone of Mizuho Securities issued a Buy rating with the price target of $ 95 on 1 day ago
- Derik De Bruin of Bank of America Securities issued a Hold rating with the price target of $ 94 on 1 day ago
- Vijay Kumar of Evercore ISI issued a Hold rating with the price target of $ 90 on 1 day ago
- Timothy Daley of Wells Fargo issued a Hold rating with the price target of $ 85 on 1 day ago
If you are wondering if HOLX is a good stock to buy, here are 3rd party ratings for HOLX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 46% (115 out of 250)
What is the sentiment on the street regarding Hologic? (Current ratings compiled by TipRanks.com)
- News Sentiment for HOLX stock: Very Bullish
- Blogger Consensus for HOLX stock: Bullish
- Media Buzz for HOLX stock: Low
- Insider Signal for HOLX stock: ―
- Investor Sentiment for HOLX stock: Very Negative
- Hedge Fund signal for HOLX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on HOLX stock including scouring the social networks like HOLX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for HOLX stock chart >>
Summary: Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
- Recent INCY Stock Price: $68.04
- Yearly Gain for INCY stock: -9.35%
- Market Cap for INCY stock: $16.80B
- P/E Ratio for INCY stock: 52.001
Will INCY's stock price go up? Is there an accurate INCY stock forecast available?
TipRanks.com reports that Incyte currently has 14 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $83.00. The target pricing ranges from a high INCY forecast of $113.00 down to a low forecast of $61.00. Incyte (INCY)’s last closing stock price was $68.04 which would put the average price target at 21.99% upside.
In addition, TradingView issued a Strong Sell rating for INCY stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on INCY stock.
Other analysts covering INCY include:
- Stephen Willey of Stifel Nicolaus issued a Hold rating with the price target of $ 73 on 22 hours ago
- Marc Frahm of Cowen & Co. issued a Buy rating with the price target of $ 93 on 22 hours ago
- Jessica Fye of J.P. Morgan issued a Hold rating with the price target of $ 70 on 22 hours ago
- Mara Goldstein of Mizuho Securities issued a Hold rating with the price target of $ 82 on 22 hours ago
If you are wondering if INCY is a good stock to buy, here are 3rd party ratings for INCY stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 34% (86 out of 250)
What is the sentiment on the street regarding Incyte? (Current ratings compiled by TipRanks.com)
- News Sentiment for INCY stock: Very Bullish
- Blogger Consensus for INCY stock: Bullish
- Media Buzz for INCY stock: High
- Insider Signal for INCY stock: Positive
- Investor Sentiment for INCY stock: Very Negative
- Hedge Fund signal for INCY stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on INCY stock including scouring the social networks like INCY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for INCY stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
